StreetInsider.com News Articles

Form 4 Corvus Pharmaceuticals, For: May 18 Filed by: MILLER RICHARD A MD

Wed, 20 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260520/26528457.html

Form 4 Corvus Pharmaceuticals, For: May 18 Filed by: MILLER RICHARD A MD

Wed, 20 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260520/26528457.html

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 16:01:00 -0400

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET.

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 16:01:00 -0400

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 16:01:00 -0400

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 16:01:00 -0400

Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260515/26505754.html

Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260515/26505754.html

Form SCHEDULE 13G Corvus Pharmaceuticals, Filed by: Sirenia Capital Management LP

Fri, 15 May 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260515/26499897.html

Form SCHEDULE 13G Corvus Pharmaceuticals, Filed by: Sirenia Capital Management LP

Fri, 15 May 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260515/26499897.html

Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald

Fri, 15 May 2026 07:33:22 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and {REMOVEPT} price target on Corvus Pharmaceuticals (NASDAQ: CRVS).

The analyst commented "Corvus presented new biomarker and longer follow-up data of Soquelitinib (SQL, ITK inhibitor) in AD (atopic dermatitis) at the Society for Investigative Dermatology today (5/14) and hosted a call. We got numerous investor inbounds on the stock weakness on a seemingly solid dataset (CRVS ~-14% vs XBI ~-0.5% intraday). We haven't heard a real bear thesis. The biomarker data may look a little "noisy," and an absence of placebo data makes the interpretation a bit ambiguous. "Selling the news" dynamic

Form 8-K Corvus Pharmaceuticals, For: May 14

Thu, 14 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26489720.html

Form 8-K Corvus Pharmaceuticals, For: May 14

Thu, 14 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26489720.html

Corvus Pharmaceuticals presents soquelitinib atopic dermatitis data

Thu, 14 May 2026 07:00:37 -0400

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) presented data from its Phase 1 trial of soquelitinib for moderate-to-severe atopic dermatitis at the Society for Investigative Dermatology Annual Meeting in Chicago.

The randomized, blinded, placebo-controlled trial enrolled 72 patients who had previously failed one prior topical or systemic therapy. Patients received 28-day or 56-day dosing regimens of soquelitinib at various doses or placebo, according to the company's press release.

In cohort 3, which received 200 mg twice daily for 28 days, 50% of soquelitinib patients achieved EASI 75, 8% achieved EASI 90, and 25% achieved IGA 0/1. In cohort 4, which received the same dose

Corvus Pharmaceuticals presents soquelitinib atopic dermatitis data

Thu, 14 May 2026 07:00:37 -0400

In cohort 3, which received 200 mg twice daily for 28 days, 50% of soquelitinib patients achieved EASI 75, 8% achieved EASI 90, and 25% achieved IGA 0/1. In cohort 4, which received the same dose

Corvus Pharmaceuticals presents soquelitinib atopic dermatitis data

Thu, 14 May 2026 07:00:37 -0400

In cohort 3, which received 200 mg twice daily for 28 days, 50% of soquelitinib patients achieved EASI 75, 8% achieved EASI 90, and 25% achieved IGA 0/1. In cohort 4, which received the same dose

Corvus Pharmaceuticals presents soquelitinib atopic dermatitis data

Thu, 14 May 2026 07:00:37 -0400

In cohort 3, which received 200 mg twice daily for 28 days, 50% of soquelitinib patients achieved EASI 75, 8% achieved EASI 90, and 25% achieved IGA 0/1. In cohort 4, which received the same dose

Corvus Pharmaceuticals presents soquelitinib atopic dermatitis data

Thu, 14 May 2026 07:00:37 -0400

In cohort 3, which received 200 mg twice daily for 28 days, 50% of soquelitinib patients achieved EASI 75, 8% achieved EASI 90, and 25% achieved IGA 0/1. In cohort 4, which received the same dose

Corvus Pharmaceuticals presents soquelitinib atopic dermatitis data

Thu, 14 May 2026 07:00:37 -0400

In cohort 3, which received 200 mg twice daily for 28 days, 50% of soquelitinib patients achieved EASI 75, 8% achieved EASI 90, and 25% achieved IGA 0/1. In cohort 4, which received the same dose

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Thu, 14 May 2026 07:00:00 -0400

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways.

Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy

Immunologic markers consistent with soquelitinib’s novel mechanism of action and clinical results

SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT)

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals,

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Thu, 14 May 2026 07:00:00 -0400

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways.

Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy

Immunologic markers consistent with soquelitinib’s novel mechanism of action and clinical results

SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT)

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals,

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Thu, 14 May 2026 07:00:00 -0400

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways.

Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy

Immunologic markers consistent with soquelitinib’s novel mechanism of action and clinical results

SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT)

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals,

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Thu, 14 May 2026 07:00:00 -0400

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways.

Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy

Immunologic markers consistent with soquelitinib’s novel mechanism of action and clinical results

SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT)

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals,

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Thu, 14 May 2026 07:00:00 -0400

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways.

Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy

Immunologic markers consistent with soquelitinib’s novel mechanism of action and clinical results

SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT)

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals,

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Thu, 14 May 2026 07:00:00 -0400

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways.

Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy

Immunologic markers consistent with soquelitinib’s novel mechanism of action and clinical results

SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT)

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals,